Inclusion Criteria:

          1. Signed written informed consent.

          2. Female patients ≥ 18 years

          3. Histologically confirmed high grade, advanced stage serous ovarian, fallopian tube or
             primary peritoneal carcinoma.

          4. Patients who have undergone primary debulking surgery and have completed standard
             first-line platinum-based chemotherapy for whom tumor tissue has been banked from
             previous abdominal surgery.

          5. Patients must have achieved a complete response to therapy

          6. Adequate hematological, hepatic and renal functions

        Exclusion Criteria:

          1. Patient having received:

               -  Neoadjuvant chemotherapy prior to debulking surgery

               -  Any cancer immunotherapy including cancer vaccines, any antibody/drug targeting T
                  cell co-regulatory proteins such as anti-Programmed cell death 1 (anti-PD1),
                  anti-Programmed death-ligand 1 (anti-PDL1) or anti-cytotoxic
                  T-lymphocyte-associated protein 4 (anti-CTL4)

          2. Patients with other active malignancy ≤ 3 years prior to registration except
             non-melanoma skin cancer, and stage 0 in situ carcinoma.

          3. Patient post-organ transplantation, including allogeneic stem cell or bone marrow
             transplantation

          4. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known AIDS
             (Acquired Immune Deficiency Syndrome)

          5. Any known allergy or reaction to eggs or attributed to compounds of similar chemical
             or biological composition to therapeutic vaccines/immunotherapeutic products

          6. Acute or chronic infection with hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)

          7. Major surgery within 4 weeks of treatment start

          8. Treatment with another investigation agent within 30 days prior to TG4050 treatment
             initiation.

          9. Patients under chronic treatment with systemic corticosteroids or other
             immunosuppressive drugs . Steroids with no or minimal systemic effect (topical,
             inhalation) are allowed.

         10. Use of non-oncology vaccine therapy for prevention of infectious diseases during the
             four-week period prior to TG4050 treatment initiation planned date.

         11. Uncontrolled intercurrent illness